Nestle set to increase stake in Aimmune Therapeutics to $273mn total

By Sean Galea-Pace
Share
The Swiss-based food manufacturing company, Nestle, is set to significantly raise its stake in drug firm, Aimmune Therapeutics, as it begins to submit a...

The Swiss-based food manufacturing company, Nestle, is set to significantly raise its stake in drug firm, Aimmune Therapeutics, as it begins to submit a marketing application for its peanut allergy drug by the end of 2018, Reuters reports.

In a deal expected to be worth $98mn, the agreement will see Nestle’s stake rise to 19% from 14.5% as of the end of February, with its total investment in the company reaching $273mn.

It has also been announced that the companies have increased their two-year strategic pact to create therapies for food allergies by an additional two years.

See more:

Wedbush Securities analyst, Liana Moussatos, commented: “Some investors were worried that Nestle might sell their original equity investment in Aimmune. However, to us, this suggests Nestle views investment in Aimmune as long-term.”

According to Chief Executive Officer, Jayson Dallas, the launch of Aimmune’s oral drug, AR101, is said to be “well beyond” the expected approval and unveiling of the drug in the US.

It is anticipated the drug will be one of the first to be made available to patients in need for treatment options.

Share

Featured Articles

Stellantis & CATL Boost EV Manufacturing Capacity

Stellantis & CATL intend to build US$4.43bn LFP battery plant in Spain by 2026, boosting EV production & advancing sustainable manufacturing

Sir David McMurty: A Visionary Engineer, Inventor and Leader

Sir David McMurty, Co-Founder of Renishaw has passed, leaving a legacy of manufacturing achievement, creating inventions and a unique company culture

IFS: Gaining New Manufacturing Value with Service Centricity

Leaders like IFS are empowering manufacturers to unlock significant business value with outcome-based service models, supercharging their customer service

Your Guide to Manufacturing LIVE Chicago

Procurement & Supply Chain

UPDATED VENUE & DATE – Manufacturing LIVE Chicago 2025

Sustainability & ESG

The Breakdown of the Global Plastics Treaty isn't the end

Sustainability & ESG